Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS1128 safety, tolerability, and pharmacokinetics in healthy participants
NCT05458076Phase 1Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of QLS-1128 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Adverse events of QLS1128. Status: unknown.
02
Drugs
QLS-1128
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05458076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05458076.